Hasty Briefsbeta

Bilingual

A NIR-Ⅱ Fluorescent Probe for Real-Time Visualization and Early Assessment of Responses to CDK4/6 Inhibitors in Breast Cancer - PubMed

5 hours ago
  • #NIR-II imaging
  • #breast cancer
  • #CDK4/6 inhibitors
  • Development of a NIR-II fluorescent probe (HSA-ICi) for real-time visualization of CDK4/6 inhibitor responses in breast cancer.
  • HSA-ICi targets the CDK4/6-cyclin D complex, shows high tumor accumulation, and enables early pharmacodynamic response monitoring.
  • Significant decrease in tumor fluorescence signal detected one week post-treatment, preceding changes in tumor volume.
  • Early signal reduction correlates with decreased pRB and Ki-67 expression in tumor tissues.
  • Probe distinguishes between CDK4/6 inhibitor-sensitive and -resistant tumors, aiding in early resistance identification.
  • Potential to facilitate timely treatment adaptation for HR+/HER2- breast cancer patients.